Skip to Main Content

Paper Details

Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with <sup>177</sup>Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
J Nucl Med
1
2023
Lu, PSA, PSMA, Patients, Prostate Cancer, RECIP, mCRPC, metastatic castration-resistant prostate cancer, patients, prostate-specific antigen, prostate-specific membrane antigen
Author NameAffiliation
Andrei GafitaDavid Geffen School of Medicine at university of california los angeles
Kathleen NguyenDavid Geffen School of Medicine at university of california los angeles
Johannes CzerninDavid Geffen School of Medicine at university of california los angeles
Jeremie CalaisDavid Geffen School of Medicine at university of california los angeles
  • 1 - 4

Datasets

Release 1.2